Romania Liver Diseases Therapeutics Market Report 2022 to 2030

Romania Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Romania liver disease therapeutics market will reach a value of $106 Mn from $67 Mn in 2022, growing at a CAGR of 6 % during 2022-30. The liver disease therapeutics market in Romania is dominated by a few domestic pharmaceutical companies such as Zentiva, Biofarm, and Antibiotics. The liver disease therapeutics market in Romania is segmented into different types of disease and different therapy types. Some of the major factors affecting the market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10ROPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Romania AUTHOR: Dr. Vishwa Modhia

Buy Now

Romania Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Romania liver disease therapeutics market will reach a value of $106 Mn from $67 Mn in 2022, growing at a CAGR of 6 % during 2022-30.

Romania is an upper-middle-income, developed country located at the crossroads of Central and Southeastern Europe. In Romania, the public and private sectors are increasingly collaborating to discover and commercialize novel medicines for liver disease. With the increasing frequency of liver disease, there is a greater need for effective medicines that can prevent or manage the progression of liver disease. As a result, there is a need for novel therapeutics that can improve patient outcomes, lower the incidence of liver-related problems, and enhance the quality of life. In Romania, liver illness is a major public health concern, with viral hepatitis being one of the biggest causes. The prevalence of chronic hepatitis B in Romania is estimated to be around 1.5 %, whereas chronic hepatitis C is expected to be around 3.5 %. Both disorders can result in liver cirrhosis and cancer.

According to the latest WHO data published in 2020 liver disease deaths in Romania reached 8,920 or 3.82% of total deaths. The age-adjusted death rate is 27.34 per 100,000 of the population ranks Romania 66^th in the world. Romania's government spent 6.3 % of its GDP on healthcare in 2020.

romania liver disease therapeutics market analysis

Market Dynamics

Market Growth Drivers

Alcohol drinking is prevalent in Romania, which is a major risk factor for liver disease. The frequency of liver disease in Romania is rising, owing to an increase in the number of people infected with NAFLD and hepatitis C virus (HCV). Because of its low labor costs, Romania boasts a diverse and competitive industry. The EU included Romania in its "Golden Growth" scheme in 2001.

Market Restraints

Because funding for liver disease research in Romania is limited, the discovery of new treatments and therapies for liver disease may be hampered. Romania's population is shrinking as a result of low birth rates and youth exodus.

Competitive Landscape

Key Players

Antibiotice: Antibiotice is a Romanian pharmaceutical company that produces a variety of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid
Biofarm: Biofarm is a Romanian pharmaceutical company that produces a range of therapeutics, including those for liver disease. Its liver disease products include Silibinin
Zentiva: Zentiva is a multinational pharmaceutical company with a significant presence in Romania. The company produces a range of therapeutics, including those for liver disease. Its liver disease products include Ursodeoxycholic acid
Gedeon Richter: Gedeon Richter is a multinational pharmaceutical company with a significant presence in Romania. The company produces a range of therapeutics, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Ademetionine

Recent Notable Updates

August 2022: Can-Fite BioPharma, a biotechnology company developing a pipeline of proprietary small molecule drugs to treat inflammatory, cancer, and liver diseases, announced today that its liver drug candidate Namodenoson has received compassionate use approval in Romania for the treatment of patients with advanced liver cancer. Namodenoson was previously approved for compassionate use in Israel, where it has been used to treat advanced liver cancer patients for several years.

Healthcare Policies and Reimbursement Scenarios

In Romania, the regulation of liver disease therapeutics is overseen by the National Agency for Medicines and Medical Devices (ANMDM), which is responsible for ensuring that all pharmaceutical products, including liver disease therapeutics, meet safety, efficacy, and quality standards. To be approved for use in Romania, liver disease therapeutics must be registered with the ANMDM, and manufacturers must comply with Good Manufacturing Practices (GMP) and other regulatory requirements. In terms of reimbursement, the National Health Insurance House (CNAS) is responsible for providing health insurance coverage to Romanian citizens.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Romania Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.